Meetings with Raquel Dancho reported by registered lobbyists. Lobbyists must report every oral, arranged meeting with an MP, minister or other designated public office holder.
Advocate to the Government to modify the CDCP to include an Alternative Benefit Clause for eligible patients that have had implants.Read more
Promoting access to oral health care for Canada's denture users, including but not limited to those living in long-term care facilities, First Nations and Inuit people, Northern Canadians, and other vulnerable populations.
Recommending the addition of a new category within Canadian Mortgage and Housing Corporation's (CMHC) Mortgage Loan Insurance (MLI) Select Program.Read more
Recommending reforming income verification rules at the Office of the Superintendent of Financial Institutions
Recommending the addition of a new category within Canadian Mortgage and Housing Corporation's (CMHC) Mortgage Loan Insurance (MLI) Select Program.Read more
Recommending reforming income verification rules at the Office of the Superintendent of Financial Institutions
CAOT is advocating for the inclusion of occupational therapists in the expanded Canada Student Loan Forgiveness ProgramRead more
CAOT is advocating for the inclusion of occupational therapists (OTs) on primary care teams in communities across Canada, so that OTs can provide low-cost, high-impact interventions that result in positive health and wellness outcomes for the people of Canada. OTs provide home assessments and modifications that allow seniors for example to stay at home and lead productive lives in their communities.
The inclusion of occupational therapists on all Primary Care Teams in communities across Canada re health system innovation and transformation.
Advocating for OTs to be designated mental health providers.
CAOT is advocating for changes to the Income Tax Act or its regulations to enable occupational therapists to complete the T2201 Disability Tax Credit Certificate.
Engage government officials to advance awareness and support for Breast Cancer Canada’s programs and initiatives, including the REAL Alliance. Facilitate the sharing of pathology report insights and collaborate on identifying actionable next steps to drive change for those affected by breast cancer.Read more
ORAL HEALTH RESEARCH, ACCESS AND DATA: increased funding for research and projects to help improve the oral health of Canadians, such as filing of submissions and advocacy for improvements to the Oral Health Access FundRead more
HEALTH HUMAN RESOURCES: discussions on addressing health human resources challenges within dentistry, including challenges in remote areas, the Canada student loan forgiveness, Canada Student Grant, PGWP for dental assistants, internationally trained dentists, administrative staffing.
DENTAL CARE FUNDING: discussions around the federal budgetary process and program development with regard to funding of dental care, including the Canadian Dental Care Plan and the Interim Federal Health Program.
ORAL HEALTH RESEARCH, ACCESS AND DATA: increased funding for research and projects to help improve the oral health of Canadians, such as filing of submissions and advocacy for improvements to the Oral Health Access Fund.Read more
DENTAL CARE FUNDING: discussions around the federal budgetary process and program development with regard to funding of dental care, including the Canadian Dental Care Plan.
HEALTH HUMAN RESOURCES: discussions on addressing health human resources challenges within dentistry, including challenges in remote areas, the Canada student loan forgiveness, internationally trained dentists, administrative staffing.
Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilitiesRead more
Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.
We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Natural Health Products Regulations – fair and consistent interpretation by the regulator. Plain Language Labeling under the self-care products framework. Personal importation of natural health products.Read more
DIGITAL HEALTH: Increased investment in providing digital, virtual and telehealth services.Read more
INTEGRATED HEALTH HUMAN RESOURCES: Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care.
PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories.
TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed.
BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care.
FEDERAL HEALTH FUNDING FOR A NEW PRIMARY CARE ACCESS FUND: Recommendation for a funding commitment to ensure that every Canadian has access to a family doctor or primary care team.
INTEGRATED HEALTH HUMAN RESOURCES
Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care.Read more
TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed.
FEDERAL HEALTH FUNDING FOR A NEW PRIMARY CARE ACCESS FUND: Recommendation for a funding commitment to ensure that every Canadian has access to a family doctor or primary care team.
PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories.
BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care.
DIGITAL HEALTH: Increased investment in providing digital, virtual and telehealth services.
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.Read more
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
Development of standards for public alerting and warning systems and the establishment of a National Public Alerting System. Immediate and long-term funding for the National Public Alerting System.Read more
Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical productsRead more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Free Trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Mark Schaan · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Alexandra Dostral · Senior Assistant Deputy Minister of Innovation, Science and Economic Development Canada, Innovation, Science and Economic Development Canada (ISED)
Samir Chhabra · Director General, Marketplace Framework Policy Branch, Innovation, Science and Economic Development Canada (ISED)
Engage with the government on small business matters, including the importance of digital tools to small business growth and advocate for balanced policymaking that preserves effective digital advertising, audience-building and personalized business solutions for small businessesRead more
The Council of Canadian Innovators (CCI) is engaging with government officials to discuss the alignment between CCI’s priorities and the federal government’s efforts to foster innovation in Canada. These discussions focus on ensuring that government programs and policies effectively support high-growth Canadian technology firms and strengthen the country’s innovation ecosystem.Read more
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector.Read more
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
Food and Drugs Act - Natural Health Products Regulations as they relate to product approvalsRead more
International trade and tariffs. Particularly related to U.S. tariffs placed on Canadian products, as well as U.S. products subject to counter tariffs imposed by the Canadian government.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.